The Study on Cognition and Prognosis in the Elderly (SCOPE) was designed to provide outcome data on cardiovascular endpoints and cognitive function in 4500 elderly hypertensive patients randomised to the angiotensin receptor blocker, candesartan, or to placebo and followed up for 4.5 years.
Introduction
The rationale for the Study on Cognition and Prognosis in the Elderly (SCOPE), at the time of its conception in the late 1990s, was the need to provide outcome data for elderly hypertensive patients treated at entry levels of 90-99 mmHg diastolic blood pressure (DBP), for whom such data were lacking, and the need to investigate the benefits of blood pressure (BP) lowering on cognitive function in the light of mounting evidence for a link between higher levels of BP and subsequent decline in cognitive function in the elderly. 1 Earlier trials of the potential benefits of drug treatment of hypertension on indices of cognitive function had produced conflicting results. [2] [3] [4] In ongoing trials, the results of other studies and the emergence of new guidelines during the conduct of such trials can severely compromise the study design, for reasons of ethics and good clinical practice. SCOPE, planned to randomise patients with BPs in the range of 160-179 mmHg systolic BP (SBP) and 90-99 mmHg DBP to the angiotensin receptor blocker (ARB), candesartan, or to placebo, and to follow approximately 4,500 patients for four years, with the objective of detecting a reduction in the primary endpoint (cardiovascular mortality, non-fatal myocardial infarction [MI], and non-fatal stroke) of 23%, having 80% power at the 5% level of significance to detect such a difference. Several secondary and tertiary endpoints were prospectively identified and included a slowing of the decline in cognitive functions in the actively treated group.
In 1999, the WHO/ISH guidelines, based on a review of the evidence base, advocated treatment of elderly patients with SBP in excess of 160 mmHg. 5 The SCOPE Steering Group, as a result, modified their trial design to include the addition of hydrochlorothiazide, at the physician's wish, and particularly in patients previously receiving antihypertensive drugs. In addition, trial physicians were permitted to prescribe other antihypertensive drugs to patients as they felt appropriate throughout the trial. In the event, because of increasing use of BP-lowering drugs in the initial placebo group, SCOPE became a comparison of candesartan-based treatment with 'other treatments'. Only 16% of the placebo group received placebo alone, resulting after four years of followup, in only 3.2/1.6 mmHg BP separating the candesartan and the placebo groups, the former having the lower pressures. This difference was far less than that used in the initial calculation of the power of the study. As such, SCOPE had insufficient power to detect a 20% reduction in the primary endpoint, and reviewers of the study must bear this in mind.
In the event, SCOPE showed a non-significant relative risk reduction of 11% in the primary endpoint (p=0.19), of which one of the components (non-fatal stroke) was reduced by 28% (p=0.04). This latter observation was not based on a prespecified subgroup analysis and thus could have been a chance finding, since it was but one of many subgroup analyses undertaken. In those patients following the original protocol (no addon drugs in the placebo group except hydropchlorothiazide), candesartan was associated with a relative risk reduction of 32% compared with placebo (p=0.012). However, cautious interpretation is necessary, because the randomisation code is broken by this form of analysis and again it was not a prespecified subgroup analysis.
On cognitive function, there was no significant difference between the two groups. Two points need to be emphasised, however. First, the small BP differences observed between the candesartan-based treatment and the control group would have drastically reduced the power to detect a difference. Secondly, the insensitivity of the MMSE scoring system to detect a decline in cognitive function at initial MMSE scores in the 30 plus range, would have made comparisons between groups difficult, if not impossible. SCOPE fell foul of changing guidelines in practice, and the inevitable impact of the reduction in power resulting from active treatment in the 'placebo' group.
Comparisons will inevitably be made with the Losartan Intervention For Endpoint reduction in hypertension (LIFE) trial, 6 in which stroke outcome was clearly reduced by the angiotensin-receptor blocker (ARB), losartan, compared with atenolol for a similar reduction in BP.
The results of other on-going studies of ARBs in hypertension, such as the Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial, 7 will contribute to the debate on the optimal treatment to prevent cardiovascular disease. In the meantime, we await further meta-analyses from the Blood Pressure Lowering Trialists Collaboration on cardiovascular outcome related to different treatment strategies for hypertension, and the results of other large ongoing trials, such as the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT) 8 and the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). 9 On the available evidence to date, the overall benefits of good BP control versus less good control would seem to outweigh any differential benefits of specific treatment strategies,but more information is required for specific high-risk patient groups, where there remain tantalising benefits beyond BP control.
